𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Reaction of dopamine with malondialdehyde: A possible underlying event in Parkinson's disease

✍ Scribed by Marco d'Ischia; Claudio Costantini; Giuseppe Prota

Publisher
Elsevier Science
Year
1993
Tongue
French
Weight
224 KB
Volume
34
Category
Article
ISSN
0040-4039

No coin nor oath required. For personal study only.

✦ Synopsis

Under physiologically relevant conditions, malondialdehyde reacts w,ith the neurotransmitter dopamine to give three major adducts that were identified as the enaminal 1, the dihydropyridine 2 and the novel oxaasabicyclo[3.3.1]nonadiene 3.

πŸ“œ SIMILAR VOLUMES

Association of a polymorphism in the dop
Association of a polymorphism in the dopamine-transporter gene with parkinson's disease
✍ Dr. David G. le Couteur; Peter W. Leighton; Sally J. McCann; Susan M. Pond πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 341 KB πŸ‘ 1 views

## Abstract The presynaptic dopamine transporter in nigral dopaminergic neurons confers susceptibility to the cytotoxic effects of the neurotoxic metabolite of 1‐methy1‐4‐phenyl‐1,2,3,6‐tetrahydropyridine. Polymorphisms in the dopamine transporter might influence the susceptibility to such toxins.

Effects of subthalamic nucleus stimulati
Effects of subthalamic nucleus stimulation on characteristics of EMG activity underlying reaction time in Parkinson's disease
✍ Hatice Kumru; Christopher Summerfield; Francesc Valldeoriola; Josep Valls-SolΓ© πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 88 KB πŸ‘ 1 views

## Abstract We examined the effects of high‐frequency deep brain stimulation of the subthalamic nucleus (STN‐DBS) on characteristics of electromyographic (EMG) activity of the agonist muscle in 8 patients with Parkinson's disease (PD). Patients were examined during STN‐DBS (ON), and 30 minutes afte

Valvular heart disease in Parkinson's di
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader-blinded monocenter echocardiography study
✍ Susann Junghanns; Joerg T. Fuhrmann; Gregor Simonis; Christian Oelwein; Rainer K πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 69 KB

## Abstract Fibrotic valvular heart disease (VHD) has been reported in association with ergot dopamine agonists (DAs), but the current database is insufficient regarding clinical relevance and comparison to data on non‐ergot DAs. We evaluated the effects of four DAs (pergolide, cabergoline, ropinir